Page last updated: 2024-11-07

kifunensine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kifunensine: inhibitor of the glycoprotein processing mannosidase I; from actinomycete Kitasatosporia kifunense 9482; structure given in first source; RN given refers to (5R-(5alpha,6beta,7alpha,8alpha,8aalpha))-isomer; RN for cpd without isomeric designation not avail 10/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130611
CHEMBL ID1233851
SCHEMBL ID2856417
MeSH IDM0180421

Synonyms (42)

Synonym
0ni8960271 ,
unii-0ni8960271
(5r,6r,7s,8r,8as)-hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-imidazo[1,2-a]pyridine-2,3-dione
CHEMBL1233851
SMP2_000350
kifunensine
kif ,
1FO3
DB02742
1PS3
imidazo(1,2-a)pyridine-2,3-dione, hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-, (5r-(5alpha,6beta,7alpha,8alpha,8aalpha))-
109944-15-2
(+)-kifunensine
fr 900494
(5r,6r,7s,8r,8as)-6,7,8-trihydroxy-5-(hydroxymethyl)-1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-2,3-dione
2WVZ
SCHEMBL2856417
(5r,6r,7s,8r,8as)-6,7,8-trihydroxy-5-(hydroxymethyl)hexahydroimidazo[1,2-a]pyridine-2,3-dione
W-200812
(5r,6r,7s,8r,8as)-6,7,8-trihydroxy-5-(hydroxymethyl)tetrahydroimidazo[1,2-a]pyridine-2,3(1h,5h)-dione
imidazo(1,2-a)pyridine-2,3-dione, hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-, (5r,6r,7s,8r,8as)-
fr-900494
kifunensine [mi]
(5r,6r,7s,8r,8as)-hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)imidazo(1,2-a)pyridine-2,3-dione
AKOS024457479
HMS3650O10
(+)-kifunensine; fr 900494;
bdbm50482721
OIURYJWYVIAOCW-PQMKYFCFSA-N
DTXSID60883199
2,6-di-tert-butylnaphthalenesulfonicacidsodiumsalt
sr-01000946312
SR-01000946312-1
Q15303950
imidazo[1,2-a]pyridine-2,3-dione,hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-, (5r,6r,7s,8r,8as)-
CS-0015246
MS-23325
HY-19332
BK164600
kifunensine- bio-x
EX-A6294
E98649

Research Excerpts

Overview

Kifunensine is an alkaloid that is produced by the actinomycete Kitasatosporia kifunense. It resembles the cyclic oxamide derivative of 1-aminodeoxymannojirimycin in structure.

ExcerptReferenceRelevance
"Kifunensine is an alkaloid that is a strong inhibitor against class I alpha-mannosidases but is only a weak inhibitor against class II alpha-mannosidases."( Comparison of kifunensine and 1-deoxymannojirimycin binding to class I and II alpha-mannosidases demonstrates different saccharide distortions in inverting and retaining catalytic mechanisms.
Kuntz, DA; Rose, DR; Shah, N, 2003
)
1.4
"Kifunensine is an alkaloid that is produced by the actinomycete Kitasatosporia kifunense and resembles the cyclic oxamide derivative of 1-aminodeoxymannojirimycin in structure. "( Kifunensine inhibits glycoprotein processing and the function of the modified LDL receptor in endothelial cells.
Elbein, AD; Kerbacher, JK; Schwartz, CJ; Sprague, EA, 1991
)
3.17

Actions

ExcerptReferenceRelevance
"Kifunensine does not inhibit the degradation of an unglycosylated substrate (lambda Ig light chains) or of chimeric mu chains extended with the transmembrane region of the alpha T cell receptor chain, implying the existence of additional pathways for extracting proteins from the endoplasmic reticulum lumen for proteasomal degradation."( Glycoprotein quality control in the endoplasmic reticulum. Mannose trimming by endoplasmic reticulum mannosidase I times the proteasomal degradation of unassembled immunoglobulin subunits.
Fagioli, C; Sitia, R, 2001
)
1.03

Treatment

ExcerptReferenceRelevance
"Treatment with kifunensine, an inhibitor of complex-type"( Proteome-wide Identification of Glycosylation-dependent Interactors of Galectin-1 and Galectin-3 on Mesenchymal Retinal Pigment Epithelial (RPE) Cells.
Geerlof, A; Götz, M; Hauck, SM; Merl-Pham, J; Obermann, J; Priglinger, CS; Priglinger, S, 2017
)
0.79

Pharmacokinetics

ExcerptReferenceRelevance
" When compared with historical data, the antibodies bearing the high mannose glycoform exhibited faster clearance rate compared with antibodies bearing the fucosylated complex glycoform, while the pharmacokinetic properties of antibodies with Man8/9 and Man5 glycoforms appeared similar."( Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.
Bayer, R; Brown, D; Chung, S; Lutman, J; Reed, C; Stefanich, E; Stephan, JP; Wong, A; Yu, M,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells."( Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
Fujiwara, H; Funamoto, S; Futai, E; Higashiura, R; Imai, S; Noguchi, N; Okuda, M; Sugimoto, H; Takahachi, M; Urano, Y, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (4)

PathwayProteinsCompounds
protein N-glycosylation processing phase (mammalian)811
protein N-glycosylation processing phase (yeast)48
protein N-glycosylation processing phase (plants and animals)811
protein N-glycosylation (yeast) processing in the ER48

Protein Targets (30)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ALPHA1,2-MANNOSIDASEHomo sapiens (human)IC50 (µMol)0.20000.200010.100020.0000AID977608
Chain A, ALPHA1,2-MANNOSIDASEHomo sapiens (human)IC50 (µMol)0.20000.200010.100020.0000AID977608
Chain A, Alpha-mannosidase IIDrosophila melanogaster (fruit fly)Ki5,200.00005,200.00005,200.00005,200.0000AID977610
Chain A, PUTATIVE ALPHA-1,2-MANNOSIDASEBacteroides thetaiotaomicron VPI-5482Ki96.000096.000096.000096.0000AID977610
Chain A, Putative Alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki96.000096.000096.000096.0000AID977610
Chain B, Alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki96.000096.000096.000096.0000AID977610
Chain A, PUTATIVE ALPHA-1,2-MANNOSIDASEBacteroides thetaiotaomicron VPI-5482Ki96.000096.000096.000096.0000AID977610
Alpha-1,2-mannosidase family proteinBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidase, putativeBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Glycoside hydrolase family 92Bacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Glycoside hydrolase family 92Bacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidase, putativeBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidase, putativeBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Putative alpha-1,2-mannosidaseBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
Alpha-1,2-mannosidase family proteinBacteroides thetaiotaomicron VPI-5482Ki185.00005.00005.00005.0000AID514924; AID514932
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1720081Inhibition of Golgi mannosidase in human HeLa cells assessed as high mannose type N-glycans accumulation by measuring reduction in cell length using ConA-AF488 at 10 uM by fluorescence microscopy analysis (Rvb = 100%)2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation.
AID1720079Inhibition of Golgi mannosidase in human HeLa cells assessed as high mannose type N-glycans accumulation by measuring increase in fluorescence intensity using ConA-AF488 at 10 uM by fluorescence microscopy analysis (Rvb = 100%)2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation.
AID1720083Inhibition of Golgi mannosidase in human HeLa cells assessed as intracellular high mannose type N-glycans accumulation by measuring increase in fluorescence intensity using ConA-AF488 at 10 uM by confocal laser scanning microscopy analysis2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation.
AID514932Inhibition of Bacteroides thetaiotaomicron GH92 alpha-mannosidase 3990 assessed as reduction of mannose release using 4NP-mannopyranoside substrate2010Nature chemical biology, Feb, Volume: 6, Issue:2
Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
AID1720080Inhibition of Golgi mannosidase in human HeLa cells assessed as high mannose type N-glycans accumulation by measuring increase in fluorescence area using ConA-AF488 at 10 uM by fluorescence microscopy analysis (Rvb = 100%)2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation.
AID1720082Inhibition of Golgi mannosidase in human OVCAR-3 cells assessed as inhibition of spheroid formation by measuring size at 10 uM upto 7 days by light microscopy analysis relative to control2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
A novel Golgi mannosidase inhibitor: Molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation.
AID514924Inhibition of Bacteroides thetaiotaomicron GH92 alpha-mannosidase 2199 assessed as reduction of mannose release using 4NP-mannopyranoside substrate2010Nature chemical biology, Feb, Volume: 6, Issue:2
Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2010Nature chemical biology, Feb, Volume: 6, Issue:2
Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2000The Journal of biological chemistry, Dec-29, Volume: 275, Issue:52
Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases.
AID1811Experimentally measured binding affinity data derived from PDB2003Biochemistry, Dec-02, Volume: 42, Issue:47
Comparison of kifunensine and 1-deoxymannojirimycin binding to class I and II alpha-mannosidases demonstrates different saccharide distortions in inverting and retaining catalytic mechanisms.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003Biochemistry, Dec-02, Volume: 42, Issue:47
Comparison of kifunensine and 1-deoxymannojirimycin binding to class I and II alpha-mannosidases demonstrates different saccharide distortions in inverting and retaining catalytic mechanisms.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (12.90)18.2507
2000's31 (33.33)29.6817
2010's35 (37.63)24.3611
2020's15 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.88 (24.57)
Research Supply Index4.55 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index50.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other92 (97.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]